{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"1450"}]}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58","value":"1240"}]}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"PK: AUC0-tlast) was reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"All part A participants who received 50 mg/m²/day irinotecan were included under this arm.","id":"OG000","title":"Part A: 50 mg/m²/Day Irinotecan"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All Part A participants who received at least one dose of irinotecan and had evaluable PK data. Per planned analysis, PK analysis was performed as per the dose of drug received.","reportingStatus":"POSTED","timeFrame":"2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)","title":"PK: (AUC0-tlast) of Irinotecan in Part A","type":"PRIMARY","unitOfMeasure":"ng*h/mL"}